Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, Virology, Picornaviruses, Human parechovirus, Antivirals, ENTEROVIRUS REPLICATION, TYPE-3 INFECTION, HIGH PREVALENCE, HPEV GENOTYPES, INFANTS, SAMPLES, A549 Cells, Animals, Antiviral Agents, Chlorocebus aethiops, HeLa Cells, High-Throughput Screening Assays, Humans, Mice, Nucleosides, Parechovirus, Vero Cells, Virus Replication, Hela Cells, 0605 Microbiology, 1108 Medical Microbiology, 1115 Pharmacology and Pharmaceutical Sciences, 3107 Microbiology, 3207 Medical microbiology, 3214 Pharmacology and pharmaceutical sciences

Abstract:

Parechoviruses A (HPeV, Picornaviridae) are neglected human pathogens that cause sepsislike illness and severe neurological complications in infants. There are no antivirals available for the treatment of HPeV infections. We here report on cell-based assays that allow for medium-throughput antiviral screening of compound libraries against HPeV. The nucleoside viral polymerase inhibitior 2’-C-methylcytidine was identified as being an in vitro replication inhibitor of HPeV1 and HPeV3 that can serve as a reference molecule for further antiviral studies.